Santhera’s DMD therapy Agamree approved for NHS use after new price deal
England’s National Institute for Health and Care Excellence (NICE) has recommended Santhera Pharmaceuticals’ treatment for Duchenne muscular dystrophy (DMD) Agamree…
Musculoskeletal Disorders
-
-
FDA lifts clinical hold on Avidity’s lead antibody conjugate therapy trial
The US Food and Drug Administration (FDA) has lifted the partial clinical hold on Avidity Biosciences’ investigational drug, delpacibart etedesiran…
-
Modalis wins FDA rare paediatric designation for CMD CRISPR therapy
Modalis Therapeutics has been awarded a rare paediatric disease designation by the US Food and Drug Administration (FDA) for its…
-
Coherus offloads Humira biosimilar Yusimry for $40m
Coherus Biosciences has divested Yusimry (adalimumab-aqvh), a biosimilar to AbbVie’s rheumatoid arthritis therapy Humira, to Hong Kong King-Friend Industrial (HKF)…
-
Midland Pharmaceuticals launches to advance spinal injury therapeutics
Scientists from the universities of Birmingham and Sheffield have partnered with NLC Health Ventures for the launch of Midland Pharmaceuticals…
-
EC approves Sandoz’s biosimilars for bone-related ailments
The European Commission (EC) has granted marketing authorisation for Sandoz’s biosimilars Wyost (denosumab) and Jubbonti (denosumab) for bone-related ailments. Wyost…
-
Alvotech and Dr Reddy’s partner to commercialise AVT03
Alvotech has entered a collaboration with Dr Reddy's Laboratories for the commercialisation of AVT03 in the US, Europe and the…
-
Neurocrine bags FDA approval for new ‘sprinkle’ Ingrezza formulation
The US Food and Drug Administration (FDA) has approved an alternative formulation for Neurocrine Biosciences’ Huntington’s disease therapy, Ingrezza (valbenazine).…
-
Juvisé licenses J&J’s MS drug Ponvory for marketing outside North America
France-based Juvisé Pharmaceuticals has acquired global marketing rights, excluding the US and Canada, for Johnson & Johnson (J&J)’s multiple sclerosis…
-
Sun Pharma initiates recall of Febuxostat for gout in US
Sun Pharmaceutical Industries has announced a recall of 55,000 bottles of Febuxostat, a medication used to treat gout, from the…
